-

Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris

The social-first campaign humorously tackles extreme wellness trends while showcasing how Ludacris incorporates One A Day® multivitamins into his daily routine for a simple and attainable approach to support his health

WHIPPANY, N.J.--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand from Bayer backed by more than 80 years of nutritional science, today announced a partnership with Grammy Award winning recording artist, actor and philanthropist Ludacris. The collaboration brings together two names with a shared commitment to simplicity, consistency, and staying power—demonstrating how effortlessly consumers can support their health in a straightforward way with One A Day®.

The “Health Doesn't Need To Be Ludacris” campaign humorously tackles extreme wellness trends while showcasing how Ludacris incorporates One A Day® multivitamins into his daily routine for a simple and attainable approach to support his health.

Share

What is the new campaign from One A Day® multivitamins?
Through a series of comedic digital videos, Ludacris contrasts over-the-top wellness trends with a simple, achievable nutritional goal, adding One A Day® to your daily routine to support your health. The “Health Doesn't Need to Be Ludacris” campaign further validates the brand’s platform “The ONE for you” demonstrating how straightforward it can be to incorporate One A Day® into your health and wellness routine for nutritional support. Ludacris highlights his personal experience incorporating One A Day® into his daily regimen to support his health versus the exaggerated wellness fads that are taking over the lives of many Americans. The campaign underscores the role One A Day® plays as an attainable nutritional goal that meets consumers where they are across age, gender, and life stage.

Why is Ludacris partnering with One A Day® multivitamins?
“I’ve been in this business 25+ years, and I know the value of keeping things consistent and simple,” said Ludacris. “That’s what drew me to One A Day®. They make nutritional support approachable for everyone, and as someone who has to wear many different hats, I love how easy it is to stay true to my wellness routine by adding a multivitamin to support my health, rather than chasing the latest trends.”

“Consumers today are inundated with complicated wellness routines and ever-changing health trends that can make taking care of yourself feel overwhelming,” said Lisa Perez, General Manager, Nutritionals, Bayer Consumer Health North America. “With our Health Doesn't Need to Be Ludacris campaign, we wanted to have fun while reminding people that supporting your health doesn’t have to be complicated. One A Day® has been rooted in nutritional science for more than 80 years, and our goal is to make it easier for people to find the ONE for you—the multivitamin that’s right for them – regardless of their age, their gender or their life stage.”

Where can consumers find more information about One A Day®?
For more information on Health Doesn't Need to Be Ludacris, follow the brand on Instagram and TikTok. With One A Day®, consumers can find the right multivitamin for their age, gender, and life stage. To find the right product for you, visit oneaday.com.

About One A Day®
One A Day® is a multivitamin and supplement brand offering specially formulated products for many members of the family. From prenatal to 65+, One A Day® offers products for different ages, genders and health goals. The portfolio includes tablet, softgel, capsule, and gummy products. One A Day® products are available at most major drug stores and retailers nationwide.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Contacts

Media Contact:
Shari K. Schnall
Bayer
Shari.Schnall@bayer.com
347-477-4356

Bayer

GER:BAYN

Release Versions

Contacts

Media Contact:
Shari K. Schnall
Bayer
Shari.Schnall@bayer.com
347-477-4356

Social Media Profiles
More News From Bayer

Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis

BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital that evaluated the investigational PET/CT radiotracer I 124 evuzamitide.1,5 The study met the primary endpoints of sensitivity (the ability of a test to identify individuals who have the condition) and specificity (the ability of a test to identify individuals who do not have the condition) for the diagnosis of...

Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic R...

Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that a broad set of data from its stroke franchise will be presented at the 2026 European Stroke Organisation Conference (ESOC), including new late-breaking analyses from its global, landmark Phase III OCEANIC-STROKE study of asundexian, an investigational oral Factor XIa inhibitor. In total, 13 abstracts will be presented, including four OCEANIC-STROKE sub-analyses. Additionally, Bayer will present nine real-world analyses examining stroke...
Back to Newsroom